FDA Approves First and Only Therapy for IgG4-RD

• Health
• Apr 05, 2025

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD).  This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD...